| Date | Title | Description |
| 19.04.2023 | Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel | Epic Sciences, Inc. announced today that the company’s 56-gene ctDNA panel for genomic profiling of metastatic breast cancer is covered by the MolDX program (administered by Palmetto GBA) that provides coverage under the Medicare program fo... |
| 17.04.2023 |
Epic Sciences Finds $24M
| San Diego-based Epic Sciences has raise $24M in a Series G funding, the company said last week. According to the company, the funding was co-led by Deerfield Management and Arsenal Capital Partners, and also included Blue Ox Healthcare Part... |
| 15.04.2023 | Epic Sciences Raises $24M in Series G Financing | Epic Sciences, a San Diego, CA-based diagnostics company, raised $24M in Series G funding.
The round, which brought the total amount to $67M, was led by Deerfield Management and Arsenal Capital Partners, with participation from Blue Ox Heal... |
| 15.04.2023 | Epic Sciences completes a $24M round to commercialize their DefineMBC tests and expand their market-facing departments | - |
| 14.04.2023 | Epic Sciences Raises $24M in Series G |
SAN DIEGO, CA, Epic Sciences, a privately held diagnostics company, has completed a $24 million Series G.
>> Click here for more funding data on Epic Sciences
>> To export Epic Sciences funding data to PDF and Excel, click h... |
| 02.07.2022 | Epic Sciences closes $43M Series F Round to expand their platform and operations into new areas | - |
| 02.06.2022 | Epic Sciences Raises 42M in First Close of Series F Funding | Epic Sciences, Inc., a San Diego, CA-based diagnostics company, closed a $43m first close of its Series F financing.
The round was led by Arsenal Capital Partners, with participation from existing investors such as Blue Ox Healthcare Partne... |
| 02.06.2022 | Epic Sciences Secures $43M Series F Financing |
SAN DIEGO, CA, Epic Sciences, a privately held diagnostics company, has completed a $43 million first close of its Series F financing.
>> Click here for more funding data on Epic Sciences
>> To export Epic Sciences funding d... |
| 01.06.2022 | Epic Sciences Raises $42M in First Close of Series F Financing to Advance Comprehensive Profiling for Metastatic Cancer Patients | Epic Sciences, Inc. ("Epic" or "Epic Sciences"), a privately held diagnostics company, has completed a $43 million first close of its Series F financing. The company will use the capital from this additional round of pri... |
| 28.03.2022 | Epic Sciences Unveils DefineMBC™, A Novel Blood-Based Test Designed To Improve Care For Metastatic Breast Cancer Patients | Multiple leading community cancer centers enrolling in Early Access Program
DefineMBC biomarkers for ongoing characterization of patients in biopharma drug trials
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (... |
| 30.01.2022 | Epic Sciences and Fulgent Genetics Collaborate to Deliver DefineMBC™ Results for Metastatic Breast Cancer Patients | Epic Sciences scales its workflow for ctDNA testing with Next Generation Sequencing Leader Fulgent
Fulgent Genetics’ expertise in high-volume testing powers Epic’s Comprehensive Cancer Profiling
Epic Sciences, Inc. today announced it has ... |
| 16.12.2021 | Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials | Comprehensive Profiling on the Epic Platform Maximizes Biomarker Analysis for Discovery and Clinical Studies
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation f... |
| 03.11.2020 | Dr. Charles Kennedy Presents at HLTH VRTL 2020 | See Charles’ Opening Keynote on Healthcare Investing & Deal Flow Outlook presented for the HLTH VRTL 2020 conference HERE.
Charles discusses the lessons learned from the COVID pandemic and the impact it will have on the healthcare indu... |
| 26.05.2020 | EPIC SCIENCES TO PRESENT MULTIPLE ABSTRACTS AT ASCO 2020 HIGHLIGHTING THE IMPORTANCE OF CTCs IN LIQUID BIOPSY | SAN DIEGO, Calif., May 26, 2020 – Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Scien... |
| 06.02.2020 | EPIC SCIENCES TO PRESENT NEW DATA DEMONSTRATING EXPANDED CLINICAL UTILITY OF AR-V7 AT 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM | Further Analysis from PROPHECY Multi-Center Trial
Data supports AR-V7 as a prognostic and predictive biomarker
Expands clinical utility of CTC-based biomarkers for patient stratification
SAN DIEGO, Calif., February 6, 2020 – Epic Science... |
| 05.12.2019 | EPIC SCIENCES TO PRESENT NEW DATA SHOWING FEASIBILITY OF ITS LIQUID BIOPSY TEST IN BREAST CANCER | San Diego, Calif. December 5, 2019 – Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatm... |
| 25.05.2019 | EPIC SCIENCES APPOINTS LLOYD SANDERS AS CHIEF EXECUTIVE OFFICER | SAN DIEGO, Calif., March 25, 2019 – Epic Sciences, Inc. (Epic) today announced that Lloyd Sanders has joined the company as president and chief executive officer. After serving nearly six years in the role, Murali Prahalad, Ph.D., has stepp... |
| 22.05.2019 | EPIC SCIENCES APPOINTS NEW CHIEF TECHNOLOGY OFFICER | San Diego – May 22, 2019 – Epic Sciences, Inc. announced today that it has named Chockalingam “Palani” Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive globa... |
| 22.04.2019 | EPIC SCIENCES APPOINTS RICHARD J. WENSTRUP, M.D. AS CHIEF MEDICAL OFFICER | San Diego, CA, April 22, 2019. — Epic Sciences, Inc. announced today the appointment of Richard J. Wenstrup, M.D. as chief medical officer. In this role, Dr. Wenstrup will lead clinical development, regulatory and medical affairs strategies... |
| 13.09.2018 | Term Sheet — Thursday, September 13 | A SUMMER OF PROMOTIONS
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
In January, BoxGroup promoted Nimi Katragadda to partner. In May, Bain Capital Ventures hired Sarah Smith as a ge... |
| 12.09.2018 | Epic Sciences Closes $52M in Series E Financing | Epic Sciences, a San Diego, CA-based developer of blood tests that predict therapeutic benefit for cancer patients, completed a $52m Series E financing.
The round was led by Blue Ox Healthcare Partners, with participation from Deerfield Man... |
| 12.09.2018 | Blue Ox Healthcare Partners Leads $52 Million Investment in Epic Sciences | NEW YORK – September 12, 2018 – Blue Ox Healthcare Partners, LLC (“Blue Ox” or the “Firm”), an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Serie... |
| 12.09.2018 | Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics | The company is developing its set of predictive tests and decision support analytics using its platform, dubbed No Cell Left Behind, which employs technology like machine learning algorithms to identify rare cancer cells in the blood. The s... |
| 12.09.2018 | Blue Ox Healthcare Partners Leads $52 Million Investment in Epic Sciences | NEW YORK--(BUSINESS WIRE)--Blue Ox Healthcare Partners, LLC , an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Series E investment in Epic Science... |
| 12.09.2018 |
Epic Sciences Gets $52M More
| San Diego-based Epic Sciences, which is developing technology around personalization of cancer treatment and management, has raised $52M more in a Series E funding, the company's lead investor said this morning. According to Blue Ox Healthc... |
| 30.04.2017 | Domain Associates Joins $40M Series D for Epic Sciences | Epic Sciences (Epic) announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabb... |
| 29.04.2017 | Epic Sciences Completes $40M Series D |
SAN DIEGO, CA, Epic Sciences has completed a $40 million Series D financing led by Hermed Capital.
>> Click here for more funding data on Epic Sciences
>> To export Epic Sciences funding data to PDF and Excel, click here
... |
| 28.04.2017 | Biopharma just can’t get enough of Epic Sciences | So what’s all the fuss about?
Epic is a liquid biopsy company that generates diagnostic information by screening a patient’s blood. It’s a high buzz field, with companies ranging from Freenome to Thermo Fisher Scientific to Guardant Health ... |
| 28.04.2017 |
Epic Sciences Raises $40M In Series D Funding
| San Diego-based Epic Sciences has raised $40M in a Series D funding, for its cancer testing technology, the company announced Friday morning. According to Epic Sciences, the funding was led by Hermed Capital, and also included Altos Capital... |
| 28.04.2017 | Term Sheet — Friday, April 28 | NEW MONEY, IPOS, PRIVATE EQUITY ACTIVISTS
Good morning, hello, hi.
Paid Content See how A.I. can protect your enterprise From ExtraHop
Aurora isn’t interested in manufacturing cars; nor does it want to be a volume producer of the many senso... |
| 28.04.2017 | Epic Sciences Completes $40M Series D Financing | Epic Sciences, a San Diego, CA-based developer of liquid biopsy tests to predict drug response in cancer patients, completed a $40m Series D financing.
The round was led by Hermed Capital, with participation from Altos Capital Partners, Dom... |
| 24.06.2016 | New blood test from Epic Sciences matches patients with PARP inhibitors | The PARP enzyme is a promising therapeutic target because it also repairs DNA damage, helping cancer cells survive. Inhibiting PARP in HRD cancer cells generates more damage than the cells can withstand, ultimately killing them. The trick i... |
| 01.06.2015 |
Epic Sciences Gets $15M In Credit Facility
| San Diego-based Epic Sciences,, a developer of diagnostics products aimed at treating and managing cancer, has expanded a credit facility it has from Silicon Valley Bank from $5M to $15M. Terms and rates on that credit facility were not ann... |
| 01.06.2015 | Epic Sciences Expands Credit Facility with Silicon Valley Bank | Epic Sciences, Inc., a San Diego, CA-based private diagnostics company that designs and develops products and offerings to personalize and advance the treatment and management of cancer, has expanded the available credit under its existing ... |
| 30.07.2014 | Epic Sciences raises $30M for “no cell left behind” test that analyzes circulating tumor cells | “Here we have a very adaptive, evolving disease – but right now, we only take a single snapshot with a biopsy,” Prahalad said. “What we really need is a movie.” Epic Sciences provides just that, he said – a noninvasive movie that helps docs... |
| 30.07.2014 | Epic Sciences Announces $30M in Series C |
SAN DIEGO, CA, Privately held biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, has raised a $30 million Series C round.
>> Click here for more funding da... |
| 30.07.2014 | Epic Sciences Completes $30M Series C Financing | Epic Sciences, Inc., a San Diego, CA-based biotech company that designs and develops novel diagnostics to personalize and advance the treatment and management of cancer, completed a $30m Series C financing.
Backers included new investors Ru... |
| 13.11.2012 | Epic Sciences Completes $13M Series B Equity Financing | Epic Sciences, Inc., a San Diego, CA-based biotech company that develops cancer diagnostics, has completed a $13m Series B equity financing.
Backers include new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments... |
| 13.11.2012 | Epic Sciences Inks $13M Series B Financing |
SAN DIEGO, CA, Private biotech company that develops breakthrough cancer diagnostics, announced today that it has completed a $13 million Series B equity financing.
>> Click here for more funding data on Epic Sciences
>> To ... |
| 13.11.2012 | Cancer diagnostics firm that can enable personalized medicine raises $13M in series B financing | “Epic’s technology has achieved an unprecedented level of sensitivity in detecting circulating tumor cells to develop crucial cancer diagnostics for the millions of patients who need to understand whether their treatment is working and the ... |
| 13.11.2012 |
Epic Sciences Gets $13M For Cancer Diagnostics
| San Diego-based Epic Sciences, a firm developing cancer diagnostics technology, announced today that it has raised $13M in a Series B equity round. The round came from Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, a... |
| 24.07.2009 |
Epic Sciences Raises $2.5M
| San Diego-based Epic Sciences, a stealth mode startup which appears related to the Scripps Research Institute, has quietly raised $2.5M in a funding round. Epic is developing analytical laboratory instruments. The funding for the firm was d... |
| - | Epic Sciences raises $30M for “no cell left behind” test that analyzes circulating tumor cells | With a simple blood test, Epic Sciences can help physicians monitor the condition and severity of a cancer patient’s cancer by analyzing the intricacies of his or her circulating tumor cells.
The San Diego company just raised $30 million in... |
| - | Cancer diagnostics firm that can enable personalized medicine raises $13M in series B financing | San Diego-based biotech firm Epic Sciences announced Tuesday that the company has raised $13 million to pursue its molecular diagnostics technology that can better detect and monitor cancer as well as enable personalize cancer treatment.
In... |
| - | Epic Sciences | “Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-... |
| - | Disease Progression Diagnostics Company Epic Sciences Raises $24 Million | Epic Sciences – a privately held diagnostics company – announced it has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last 12 months. And the company will use the f... |
| - | Biopharma just can’t get enough of Epic Sciences | Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy... |
| - | Epic Sciences raises $52M Series E round to advance liquid biopsy diagnostics | A diagnostics company plans to use its latest round of venture capital funding to advance liquid biopsy tests designed to predict how patients respond to drugs.
San Diego-based Epic Sciences said Wednesday that it had raised a $52 million S... |
| - | New blood test from Epic Sciences matches patients with PARP inhibitors | San Diego-based liquid biopsy company Epic Sciences has announced a new blood test that may quickly identify cancer patients who respond to a promising class of drugs called poly ADP ribose polymerase (PARP) inhibitors. The test works by id... |
